Zobrazeno 1 - 10
of 1 045
pro vyhledávání: '"A. V. Tinker"'
Autor:
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 14, Iss 1 (2024)
Aim: To understand the impact of the niraparib individualized starting dose (ISD), compared with fixed starting dose (FSD), on the cost of hematologic adverse event (AE) management from a US payer perspective. Methods: The frequencies of grade ≥3
Externí odkaz:
https://doaj.org/article/fd0ad03a518f43ba94492c44289ec241
Autor:
Nancy Guo, Aijun Yang, Fabiha Binte Farooq, Shreena Kalaria, Elena Moss, Lindsay DeVorkin, Mary Lesperance, François Bénard, Don Wilson, Anna V. Tinker, Farouk S. Nathoo, Phineas T. Hamilton, Julian J. Lum
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Unlike other histological types of epithelial ovarian carcinoma, clear cell ovarian carcinoma (CCOC) has poor response to therapy. In many other carcinomas, expression of the hypoxia-related enzyme Carbonic anhydrase IX (CAIX) by cancer cell
Externí odkaz:
https://doaj.org/article/95ede8de1ca14914bdce66a61cd611f5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
The Yale Law Journal, 1902 May 01. 11(7), 376-376.
Externí odkaz:
https://www.jstor.org/stable/780810
Autor:
John Hilton, Karen Gelmon, Philippe L. Bedard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek Jonker, Aaron R. Hansen, Zachary W. Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu Chen, Deb Kellar, Irene Li, Sung-Eun Lee, Takako Kono, Brian Y. C. Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria-Bretones, Eric Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparicio, David W. Cescon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
G-quadruplex stabilizers, including CX-5461, exhibit synthetic lethality with loss of BRCA1/2 in preclinical models. Here the authors report the results of a phase I study of CX-5461 in patients with solid tumors enriched for DNA-repair deficiencies.
Externí odkaz:
https://doaj.org/article/ee095627571b4e258e1890f77d3d7597
Autor:
Anna V. Tinker, Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, Amit M. Oza
Publikováno v:
Current Oncology, Vol 29, Iss 6, Pp 4354-4369 (2022)
The majority of patients with advanced, high-grade epithelial-tubo ovarian cancer (EOC) respond well to initial treatment with platinum-based chemotherapy; however, up to 80% of patients will experience a recurrence. Poly(ADP-ribose) Polymerase (PARP
Externí odkaz:
https://doaj.org/article/fe8a21f7885c4aed92258cf4d73a89b6
Autor:
Anna V. Tinker, Neesha C. Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian, Stephen A. Welch, Alon D. Altman
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background and objectives: Endometrial cancer is a common malignancy and recurrences can be fatal. Although platinum-pretreated endometrial tumors are commonly treated with anthracyclines and taxanes, there is no current standard of care. Both immune
Externí odkaz:
https://doaj.org/article/39f2a9177c624dc4966f99714f895875
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of ‘synthetic lethality’ is exploited by PARPi in tumors with defects in DNA repair pathways, particula
Externí odkaz:
https://doaj.org/article/8647ec783b77428fa1c329a92662d500
Autor:
Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 c
Externí odkaz:
https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
Autor:
Lucy Gilbert, Ana Oaknin, Prafull Ghatage, Rebecca Kristeleit, Wei Guo, Sharad Ghamande, Valentina Boni, Jubilee Brown, Xinwei Han, Vanessa Samouëlian, Ellie Im, Renaud Sabatier, Anna V Tinker, David M O’malley, Bhavana Pothuri, Cara Mathews, Jennifer Veneris, Tao Duan, Linda Duska, Joshua Press, Charles Leath III, Sybil Zildjian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/e14cae0105ca4a77863badc972ff7d01